

Trajan Scientific and Medical

Global Corporate Headquarters 7 Argent Place, Ringwood Victoria 3134, Australia Tel: +61 (0) 3 9837 4200 www.trajanscimed.com

Trajan Group Holdings Limited ACN 152 617 706

ASX RELEASE

Trajan FY25 Half Year Results and Investor Webcast Notification

03 February 2025 - Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) today advises it will release its Half Year Results for the Financial Year ending 30 June 2025 (FY25), on Thursday 27 February 2025.

Investors are invited to join a live webcast and Q&A hosted by Trajan CEO and Managing Director, Stephen Tomisich and Chief Financial Officer Alister Hodges, on Thursday 27 February 2025 at 9:30am Australian Eastern Daylight Time (AEDT). Investors are invited to submit questions beforehand via the webinar registration page.

To register for the webcast, please follow this link:

https://trajanscimed.zoom.us/webinar/register/WN_YGGOM-qeSQeW7ldf10W_sA

Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.

Authorised for ASX release by the Company Secretary of Trajan Group Holdings Limited

END

Media

Contact:

Investors

Rebecca Wilson Ana Luiza Graça Harrop

Marie Krstic

Amy Miller investorrelations@trajanscimed.com media@trajanscimed

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe